10 years of CSCO: the golden years of new cancer drugs in China

Author: Xixi

The Chinese Society of Clinical Oncology (CSCO), established in 1997, is the most well-known and authoritative professional academic organization in the field of clinical oncology in China.

Similar to the conventions of international conferences, the dazzling conference agenda is divided into Plenary Sessions and major thematic sub-venues according to the scope of the audience; different types are divided into conference reports, special speeches, paper speeches, and so on

Regardless of the keynote reports on basic and translational research, there are many research data on innovative anti-tumor drugs that are worthy of attention every year

2012: The beginning of the Tinib Big Bang, the year of multi-target TKI

Sit on the time machine and go back to 2012

At that time, the plenary session had not yet included academic content, and oral presentations related to drug clinical research were scattered in the five sub-venues on the morning of the first day

At that time, the "Tinib Big Bang" had just begun-China's first generation of EGFR-TKI icotinib with independent intellectual property rights (listed in 2011), and Boehringer Ingelheim's first oncology drug, and also domestic Together with the first approved second-generation EGFR-TKI afatinib (launched in 2017), it opened the endless involution and evolution of precision targeted drugs

At that time, multi-targeted TKI was still "sweet and sweet"-the world's first small-molecule anti-angiogenesis targeted drug approved for the treatment of advanced gastric cancer emerged, but today it seems that apatinib has expanded after its launch in 2014 The pace of the indication was not smooth, and it was not until January this year that the second indication (second-line advanced liver cancer) was finally approved

2013: Innovation is difficult, continuous innovation is even more difficult

Different from the five major conference venues in 2012, in 2013, a special FACO Symposium (FACO Symposium) was set up on the basis of the four major conference venues, which has become increasingly internationalized

From the perspective of original paper exchanges, how to understand the "continuous innovation" emphasized by the theme? ——Axitinib and Sorafenib are used for the second-line treatment of advanced renal cancer, and Pezopanib and sunitinib are used for the first-line treatment of advanced renal cancer; Tiggio capsules (S1) appearing for two consecutive years The combination plan, docetaxel combined with capecitabine.

2014: Bring in, go out

According to incomplete research, the 2014 CSCO annual meeting added a Plenary to the opening ceremony for the first time, and created the lifetime achievement award and annual achievement awards that have been inherited to the present

At that time, osimertinib was also called AZD9291, and it was still in the early stage of clinical exploration.

How to expand international horizons? Both the LUX-Lung 6 study of afatinib and the CONCUR study of regorafenib are both subgroup analysis and interpretation of the global large-scale phase III study of foreign-funded pharmaceutical companies.

In addition, it is proud that the national multi-center phase III study of apatinib in the treatment of advanced gastric cancer prompted Chinese scholars to stand for the first time at the ASCO conference in 2014 to conduct oral reports in the field of gastrointestinal tumors

Bring in with one hand and walk out with one foot

2015: From "microphone" to "sound tube"

In 2015, CSCO officially became a national first-level society

Professor Wu Yilong said in an interview that year that CSCO will slowly complete the transition from "microphone" to "sounding tube" and make China's own "good voice"

The JMIT study for East Asian populations did not use platinum-containing compound drugs but used pemetrexed plus gefitinib alone to reduce side effects and improve patient compliance on the basis of prolonging PFS, which is a treatment zone for patients with EGFR mutations.
Come to new thinking
.

The other two CTONG-1102 studies and FOWARC studies were initiated and carried out by Chinese scholars, and they also made valuable explorations in the field of initial treatment of advanced NSCLC and locally advanced rectal cancer
.

2016: A single spark can start a prairie fire

Since 2016, CSCO has issued a series of guidelines for malignant tumors, effectively guiding the clinical practice of oncologists in China and becoming the most influential guidelines for diagnosis and treatment
.

Standardized fine management according to the guidelines is one aspect, and the concept of precise medical treatment based on biomarker segmentation of the population has also attracted more and more attention
.

Look at the three original studies that were selected for the plenary meeting that year.
One responded to the eagerly concerned about the progress of intracranial disease by lung cancer doctors, one targeted ROS1-positive NSCLC population, and the other targeted RAS wild-type advanced colorectal cancer patients
.
The fire of type-based treatment and precision medical treatment has been raging to this day
.

2017: CSCO’s 20th Anniversary, a milestone new drug witness

In 1997, the Chinese Anti-Cancer Association Clinical Oncology Collaborative Center (the predecessor of CSCO) was formally established and held its first annual meeting
.
After wind and rain and seeing the world, CSCO has gone through a 20-year journey in 2017
.
The heavy research at this year's general assembly has somewhat of a milestone
.

Fruquintinib is the first innovative drug approved by Hutchison Whampoa since its establishment 16 years ago, and the first new anti-tumor drug successfully completed in China from discovery to Phase 3 clinical trials
.
The research of FRESCO, which has been sharpened for ten years, was published in the Journal of the American Medical Association (JAMA) the following year
.

As for the second-generation EGFR-TKI dacotinib, it is another level of innovation
.
According to PI Wu Yilong: “Dacitinib was originally planned to give up due to its high toxicity and no significant advantages in curative effect
.
However, from the perspective of researchers, dacomitinib is more effective than one- or three-generation TKIs on EGFR.
Inhibition is more broad-spectrum.
If it is applied early to inhibit the pathways that may produce resistance, the therapeutic potential is very good
.
Based on this reasonable assumption, a first-line head-to-head ARCHER 1050 study of gefitinib was carried out
.
"

It can be seen that the right to speak is not spoken out, but is paved step by step with strength
.

2018: The immune cyclone strikes, and the original research heats up

On June 15, 2018, O drug was launched in China, becoming the first PD-1 inhibitor approved for marketing in China
.
Not surprisingly, the era of immunotherapy also swept CSCO that year
.

In addition, China's independent innovative anti-tumor drugs Anlotinib, Fruquintinib, and Pirrotinib will also be launched in 2018.
CDE with the theme of "Clinically value-oriented, accelerating the research and development of China's original tumor drugs" China's original anti-tumor drug forums came into being, and they were very popular
.

Also in 2018, CSCO added a special special session on clinical research data of innovative drugs, mainly for the development of new drugs without compromising confidentiality.
The preliminary results of phase I and phase II clinical trials will be announced in advance at the conference, thereby promoting The peers learn from each other to avoid repeated product development of pharmaceutical companies and reduce the waste of social resources
.

2019: local data, innovation and precision

This year, the classic plan and local data complement each other-the CHANGE-2 study uses the Chinese own data to establish the first-line treatment of cetuximab for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Status
.

This year, innovative and precise concepts blossomed everywhere-FRESCO's study of liver metastasis subgroups had outstanding benefits, and Anlotinib was effective in expanding to medullary thyroid cancer
.

There is no doubt that immunotherapy is the most popular
.
However, PD-1 is not invincible.
The CheckMate-331 study of nivolumab for the second-line treatment of recurrent SCLC failed miserably
.

2020: The rise of domestic PD-1, biosimilars are at the time

In 2020, the sudden new crown epidemic disrupted everyone's rhythm
.
For the first time, the CSCO Conference also adopted the simultaneous combination of online and offline to create a "CSCO Annual Conference Academic Week" with eight days and five places
.

This has been a difficult year, and it is also a year for China to independently research and develop new drugs to "offer the market
.
"

The RATIONALE-307 study of BeiGene tislelizumab and the POLARIS-03 study of Junshi teriprizumab-the domestic PD-1 was officially unveiled at the CSCO General Assembly for the first time
.

However, being rejoiced by the improvement of drug accessibility, PD-1 is so unprepared to be involved: the cruelty of medical insurance negotiations is embarrassing, and the sight of excessive competition raises vigilance
.
The window of opportunity for first-in-class drugs to fast-follow drugs is getting shorter and shorter, and "source innovation" is being mentioned more and more times on major occasions
.

On the other hand, as more and more original biopharmaceutical patents expire, biosimilars are gradually showing a trend of vigorous development.
The bevacizumab biosimilar HLX04 of Fuhong Henlius is one of the typical cases
.

2021: Biotech is ready to go, ADC wave hits

The 24th National Conference on Clinical Oncology and the 2021 CSCO Annual Conference will be held soon.
In addition to being still affected by the epidemic, it is especially worth noting that there are two "unfamiliar faces" in the agenda of the plenary meeting.
The reports are all from China's local emerging pharmaceutical companies
.

MRG002 is a recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate under development by Meac, and will soon announce the results of an exploratory study in patients with HER2-positive advanced solid tumors
.
It is worth mentioning that MRG002 adopts a Sino-US dual reporting strategy.
In May 2020, it has obtained IND approval from the US FDA to enter the clinical study of HER2-positive gastric cancer/gastroesophageal junction cancer
.
Shanghai Meacco is currently a wholly-owned subsidiary of Lepu Biotechnology Co.
, Ltd.
Lepu Bio has submitted its Hong Kong stock IPO application in April this year
.

Taletrectinib (AB-106) is an NTRK/ROS1 inhibitor.
It was originally developed by Japan's Daiichi Sankyo Co.
, Ltd.
, and introduced into China by Baoyuan Biotechnology, and began a phase II clinical trial in the Chinese population
.
The meeting will announce the preliminary results of the Phase II TRUST study of AB-106 in the treatment of ROS1-positive non-small cell lung cancer
.

Antibody-conjugated drugs (ADC), dual-target small molecule inhibitors, Sino-US double-reports, lincense-in.
.
.
The pace of the future seems to be getting closer
.

There are still 7 days before the opening of the CSCO annual meeting in 2021 (Source: CSCO official website)

postscript

Ten years of time passed in a flash, from TKI targeted drugs, immunotherapy to new ADC drugs; from me-too, fast follow to me better, first in class; from the interpretation of the Chinese subgroup of research initiated by foreign pharmaceutical companies to the local Pharmaceutical companies initiate clinical trials of new drugs independently; from import dependence, domestic substitution to Sino-U.
S.
dual reporting.
.
.
CSCO's previous general meetings are a silent mirror, reflecting that domestic pharmaceutical companies are developing iterations at an unprecedented speed There are also more and more "good voices" of Chinese researchers themselves
.

As for where will it go in the future? No one knows
.
Let history tell the future!